IDL-2965(IDL-2965) - 药物靶点：αvβ1 x αvβ3 x αvβ6_在研适应症：特发性肺纤维化，非酒精性脂肪性肝炎_专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点

αvβ1 x αvβ3 x αvβ6

作用机制

αvβ1抑制剂(整合素α-V/β-1复合体抑制剂)、αvβ3拮抗剂(整合素α-V/β-3复合体拮抗剂)、αvβ6拮抗剂(整合素α-V/β-6复合体拮抗剂)

治疗领域

消化系统疾病呼吸系统疾病其他疾病

在研适应症

特发性肺纤维化非酒精性脂肪性肝炎

非在研适应症-

原研机构

Indalo Therapeutics, Inc.

在研机构

Indalo Therapeutics, Inc.

非在研机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

1

项与 IDL-2965 相关的临床试验

NCT03949530 / Terminated临床1期

IDL-2965 - A Phase I, Randomized, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Safety, Tolerability, and Pharmacokinetic Study in Healthy Subjects and Subjects With Idiopathic Pulmonary Fibrosis (IPF)

The purpose of this study is to test the safety and tolerability of the drug candidate IDL-2965 and to see how it is absorbed, processed, and removed by the body.

开始日期2019-04-16

申办/合作机构

Indalo Therapeutics, Inc.

100 项与 IDL-2965 相关的临床结果

登录后查看更多信息

100 项与 IDL-2965 相关的转化医学

登录后查看更多信息

100 项与 IDL-2965 相关的专利（医药）

登录后查看更多信息

1

项与 IDL-2965 相关的文献（医药）

2023-06-01·American Journal of Physiology-Cell Physiology

Combined application of biosponges and an antifibrotic agent for the treatment of volumetric muscle loss

Article

作者: Shringarpure, Saloni ; Johnson, David ; Au, Jeffrey ; Griggs, David W ; West, Charles ; Robinson, Jessica ; Tobo, Connor ; Garg, Koyal ; Mottaleb, M Abdul

Volumetric muscle loss (VML) causes irrecoverable loss of muscle mass and strength and results in permanent disability. VML injury shows extensive fibrosis, which impedes functional tissue regeneration. Our lab has created a biosponge scaffold composed of extracellular matrix (ECM) proteins (i.e., biosponge) that can enhance muscle regeneration and function following VML. In this work, a potent small molecule inhibitor of alpha v-subunit containing integrins known as IDL-2965 was incorporated into the biosponges for localized suppression of fibrosis post-VML. Our results demonstrate that local delivery of IDL-2965 via the biosponges attenuated the deposition of fibrotic tissue preceded by a downregulation of profibrotic genes in VML-injured muscles. The reduction in fibrotic tissue had no detrimental effects on muscle mass, function, size, or vascularity. Overall, these findings suggest that the codelivery of biosponges and IDL-2965 is a safe and effective strategy for the mitigation of fibrotic tissue deposition in VML-injured muscles.

100 项与 IDL-2965 相关的药物交易

登录后查看更多信息